openPR Logo
Press release

Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-acting Biosimilars

09-06-2018 02:58 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Insulin Biosimilars Market, by Biosimilar Type Rapid-acting

Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million people died due to the disease in 2012. Insulin biosimilar has the ability to increase access to treatment of diabetes mellitus among the patients while reducing treatment costs.

Get The Holistic SAMPLE Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1750

Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American Society For Metabolic And Bariatric Surgery report, obesity was a major independent risk factor for developing the disease, and more than 90% of type 2 diabetics population are overweight or obese due to growing adoption of unhealthy lifestyle. Insulin is distributed and manufactured by small number of multinational companies in emerging economies, beyond the established biosimilar manufactures, and a handful of small players are developing insulin manufacturing capacities based on modern biotechnological methods in turn, boosting growth of the insulin biosimilars market size.

Insulin Biosimilars Market – Dynamics

Increasing number of manufacturers are developing biosimilar insulin to provide clinical aid that are similar to current insulin analogs at the more affordable price. Moreover, the patents of several insulin manufacturing companies are soon expected to lose patent protection, For instance, LEVEMIR an Insulin detemir by Novo Nordisk is going to lose its patent rights in year 2019, which is influencing numerous pharmaceutical key manufacturers to develop alternatives to patents, referred as biosimilar. The low cost of biosimilar insulin for diabetes treatment and effectiveness is helping treat patients suffering from diabetes mellitus. Companies are also focusing on developing medical devices that allows for less painful and safe delivery of the biosimilar insulin treatment, which in turn, is boosting market growth. Government agencies are focusing on the endorsement of insulin biosimilar by funding research and development. Furthermore, rising geriatric population across the globe and increasing demand for rapid-acting insulin analogues is boosting growth of the insulin biosimilar market. For instance, according to a consensus report published in 2012 American Diabetes Association, showed over 25% of the U.S. population aged ≥65 years suffered from diabetes.

However, critical regulatory requirements for approval of insulin biosimilar products besides strong opposition from branded manufactures regarding patent rights, high cost of production, manufacturing complexities, and various safety concerns associated with changes in drug formulations pose as factors hampering growth of the insulin biosimilars market.

Click To Reading More On
https://www.coherentmarketinsights.com/ongoing-insight/insulin-biosimilars-market-1750

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website:https://www.coherentwire.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-acting Biosimilars here

News-ID: 1224840 • Views:

More Releases from Coherent Market Insights

Bispecific Antibodies Market Set to Witness Steady Growth through (2024-2031) | Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc
Bispecific Antibodies Market Set to Witness Steady Growth through (2024-2031) | …
Bispecific Antibodies Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "Bispecific Antibodies Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Bispecific Antibodies market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables, and charts, as well as insightful
Plant Tissue Culture Market Projected To Witness Substantial Growth, 2024-2031 | Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc.
Plant Tissue Culture Market Projected To Witness Substantial Growth, 2024-2031 | …
Plant Tissue Culture Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "Plant Tissue Culture Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Plant Tissue Culture market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables, and charts, as
Ataxia Market Set to Witness Significant Growth by 2024-2031 | Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc
Ataxia Market Set to Witness Significant Growth by 2024-2031 | Pfizer, Inc., CRI …
Ataxia Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "Ataxia Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Ataxia market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables, and charts, as well as insightful analysis. The Ataxia
U.S. Imaging Services Market Set to Witness Steady Growth through (2024-2031) | Medica Group Plc., Dignity Health, InHealth Group, Alliance Medical, RadNet, Inc
U.S. Imaging Services Market Set to Witness Steady Growth through (2024-2031) | …
U.S. Imaging Services Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "U.S. Imaging Services Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the U.S. Imaging Services market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables, and charts, as

All 5 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.